Subscribe
Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.
ImmunityBio, BeiGene Strike Deal to Conduct Phase III Trial for Tislelizumab, Anktiva in Advanced or Metastatic Non-Small Cell Lung Cancer
Exploring Biopharma's Dealmaking Terrain, Roadmap in China
Sen-Jam Partners Strikes Deal with 5 Horizons Capital to Support Phase II Trial of SJP-001 for Inflammation, Metabolic Health
Teva Agrees to Strategic Partnerships with Formycon AG, Klinge Biopharma, & Samsung Bioepis
